Altimmune Stock (NASDAQ:ALT)
Previous Close
$8.18
52W Range
$5.28 - $14.84
50D Avg
$7.84
200D Avg
$7.44
Market Cap
$586.78M
Avg Vol (3M)
$3.05M
Beta
0.07
Div Yield
-
ALT Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
ALT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| FBIO | Fortress Biotech, Inc. |
| ACAD | ACADIA Pharmaceuticals Inc. |
| CABA | Cabaletta Bio, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| AVXL | Anavex Life Sciences Corp. |
| ATHA | Athira Pharma, Inc. |
| BIVI | BioVie Inc. |
| VSTM | Verastem, Inc. |
| ARDX | Ardelyx, Inc. |
| INMB | INmune Bio, Inc. |
| ZURA | Zura Bio Limited |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| SAVA | Cassava Sciences, Inc. |
| CGTX | Cognition Therapeutics, Inc. |
| HEPA | Hepion Pharmaceuticals, Inc. |